Very good point. We also need to be aware of the total potential of the Halo contract for their Recombinant Human Hyaluronidase. Per their pipeline, collaborators are:
Roche (Total of 9 potential targets)
Pfizer (Total of 6 potential targets)
Janssen (Total of 5 potential targets)
AbbVie (Total of 9 potential targets)
Lilly (Total of 5 potential targets)
Bristol-Myers Squibb (Total of 11 potential targets)
Alexion (Total of 4 potential targets)
Undisclosed
So I just wanted to point out that we should be in contention/competition for any of these targets that get selected by their collaborators. With our history of on-time, high-quality, and competitive-priced deliveries, we should hold a priority position in the pecking order. Lias mentioned Shire as one of the Halo collaborators for whom we will be providing that product. Shire (about to be a Takeda company) may be the "undisclosed" mentioned above. So on the one hand, Halo collaborators may be "low hanging fruit", we have already discussed that Lias said they would rather Halo be 5% of our business rather than 95%. So obviously, the majority of of our sales efforts will be on acquiring new business not under the Halo umbrella. In my opinion, the near future looks bright.
News 
Market Data 
Discover 
